AFREGS Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==AFREGS Trial== ===Objective=== To study the angiographic and clinical effects of increasing HDL levels with pharmacologic tre..." |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To study the angiographic and clinical effects of increasing HDL levels with pharmacologic treatment. | To study the angiographic and clinical effects of increasing HDL levels with pharmacologic treatment. | ||
==Methods== | |||
The Air Force Regression Study (AFREGS) was a randomized, double- blinded, placebo controlled trial with 143 patients younger than 76 years of age with low [[HDL]] levels and angiographically evident [[coronary artery disease]]. These patients were randomly allocated to the [[gemfibrozil]], [[niacin]], [[cholestyramine]]and corresponding placebo, with aggressive dietary and lifestyle intervention at baseline. They were then followed up for a period of 30 months for clinical events which includes hospitalization for [[angina]], [[myocardial infarction]], [[transient ischemic attack]] and [[stroke]], [[death]] and other cardiovascular procedures. | The Air Force Regression Study (AFREGS) was a randomized, double- blinded, placebo controlled trial with 143 patients younger than 76 years of age with low [[HDL]] levels and angiographically evident [[coronary artery disease]]. These patients were randomly allocated to the [[gemfibrozil]], [[niacin]], [[cholestyramine]]and corresponding placebo, with aggressive dietary and lifestyle intervention at baseline. They were then followed up for a period of 30 months for clinical events which includes hospitalization for [[angina]], [[myocardial infarction]], [[transient ischemic attack]] and [[stroke]], [[death]] and other cardiovascular procedures. | ||
==Results== | |||
* The pharmacologically treated group had a 20% decrease in total cholesterol, 36% increase in HDL cholesterol, 26% decrease in [[LDL]] cholesterol and a 50% reduction in triglyceride levels compared to the placebo group. | * The pharmacologically treated group had a 20% decrease in total cholesterol, 36% increase in HDL cholesterol, 26% decrease in [[LDL]] cholesterol and a 50% reduction in triglyceride levels compared to the placebo group. | ||
* Focal coronary stenosis showed an increase of 1.4% in the placebo and a decrease of 0.8% in the drug group. | * Focal coronary stenosis showed an increase of 1.4% in the placebo and a decrease of 0.8% in the drug group. | ||
* 26% of patients in the [[placebo]] group reached a composite cardiovascular event end point whereas the same was seen in 13% of patients in the drug group. | * 26% of patients in the [[placebo]] group reached a composite cardiovascular event end point whereas the same was seen in 13% of patients in the drug group. | ||
==Conclusion== | |||
Pharmacologic regimens aimed at raising HDL cholesterol levels improved the [[cholesterol]] levels, slowed the progression of [[stenosis]], and prevents cardiovascular events in some who exercise regularly and are on a low-fat diet.<ref name="pmid15657157">{{cite journal |author=Whitney EJ, Krasuski RA, Personius BE, ''et al.'' |title=A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events |journal=[[Annals of Internal Medicine]] |volume=142 |issue=2 |pages=95–104 |year=2005 |month=January |pmid=15657157 |doi= |url=}}</ref> | Pharmacologic regimens aimed at raising HDL cholesterol levels improved the [[cholesterol]] levels, slowed the progression of [[stenosis]], and prevents cardiovascular events in some who exercise regularly and are on a low-fat diet.<ref name="pmid15657157">{{cite journal |author=Whitney EJ, Krasuski RA, Personius BE, ''et al.'' |title=A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events |journal=[[Annals of Internal Medicine]] |volume=142 |issue=2 |pages=95–104 |year=2005 |month=January |pmid=15657157 |doi= |url=}}</ref> | ||
Revision as of 23:00, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
AFREGS Trial On the Web |
|
American Roentgen Ray Society Images of AFREGS Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To study the angiographic and clinical effects of increasing HDL levels with pharmacologic treatment.
Methods
The Air Force Regression Study (AFREGS) was a randomized, double- blinded, placebo controlled trial with 143 patients younger than 76 years of age with low HDL levels and angiographically evident coronary artery disease. These patients were randomly allocated to the gemfibrozil, niacin, cholestyramineand corresponding placebo, with aggressive dietary and lifestyle intervention at baseline. They were then followed up for a period of 30 months for clinical events which includes hospitalization for angina, myocardial infarction, transient ischemic attack and stroke, death and other cardiovascular procedures.
Results
- The pharmacologically treated group had a 20% decrease in total cholesterol, 36% increase in HDL cholesterol, 26% decrease in LDL cholesterol and a 50% reduction in triglyceride levels compared to the placebo group.
- Focal coronary stenosis showed an increase of 1.4% in the placebo and a decrease of 0.8% in the drug group.
- 26% of patients in the placebo group reached a composite cardiovascular event end point whereas the same was seen in 13% of patients in the drug group.
Conclusion
Pharmacologic regimens aimed at raising HDL cholesterol levels improved the cholesterol levels, slowed the progression of stenosis, and prevents cardiovascular events in some who exercise regularly and are on a low-fat diet.[1]
References
- ↑ Whitney EJ, Krasuski RA, Personius BE; et al. (2005). "A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events". Annals of Internal Medicine. 142 (2): 95–104. PMID 15657157. Unknown parameter
|month=ignored (help)